Biogen (BIIB) and Eisai's Leqembi medicine has been approved to treat mild cognitive impairment in early stages of Alzheimer's disease, the European Commission said Tuesday.
The medicine is for use in patients who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain, the Commission said.
The approval makes Leqembi the first such medicine to be authorized in the EU, it added.
Biogen and Eisai did not immediately respond to MT Newswires' requests for comment.
Price: 117.13, Change: -2.13, Percent Change: -1.79
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。